Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

研究方向

Immunology/Inflammation 相关产品(4245)

  • GC68873 structure
    GC68873Citric acid trisodium
    CAS: 68-04-2
    纯度: >98.00%

    Citric acid trisodium 是一种天然防腐剂和食品酸味增强剂。Citric acid trisodium 诱导细胞凋亡 (apoptosis) 和细胞周期停滞在 G2/M 期和 S 期。Citric acid trisodium 通过降低抗氧化酶活性引起肝脏的氧化损伤。Citric acid trisodium 对小鼠造成肾毒性。

  • GC68897 structure
    GC68897CpG ODN 10101
    CAS: 1234402-77-7
    纯度: >94.00%

    CpG ODN 10101 是一种合成寡脱氧核苷酸 (ODN),是一种 Toll 样受体 9 (TLR9) 激动剂。 当与 HH2(VQLRIRVAVIRA-NH2) 结合使用时,CpG ODN 10101 是一种有效的体外细胞因子/趋化因子表达诱导剂。 CpG ODN 10101 诱导树突状细胞 (DC) 分泌 IFN 并刺激 B 细胞。CpG ODN 10101 具有抗病毒和免疫调节特性,可影响慢性 HCV 感染。

  • GC68907 structure
    GC68907CTX-471
    CAS: 2377152-49-1
    纯度: >99.00%

    CTX-471 是 CD137 的全人源单克隆抗体。CTX-471 对重组人、食蟹猴 CD137 和小鼠 CD137 具有结合亲和力,Kd 值分别为 50 nM、61 nM 和 748 nM。CTX-471 可用于免疫调节和癌症的研究。

  • GC68916 structure
    GC68916CWI1-2
    CAS: 2408590-36-1
    纯度: >98.00%

    CWI1-2是一种选择性抑制m6A识别蛋白IGF2BP2的抑制剂,能够破坏IGF2BP2与m6A修饰的目标转录本之间的相互作用。

  • GC68961 structure
    GC68961Demethyleneberberine chloride
    CAS: 16705-03-6
    纯度: >98.00%

    Demethyleneberberine chloride 是一种天然线粒体靶向抗氧化剂。Demethyleneberberine chloride 通过抑制 NF-κB 通路和调节 Th 细胞的平衡来减轻小鼠结肠炎并抑制炎症反应。Demethyleneberberine chloride 可作为 AMPK 激活剂,用于非酒精性脂肪性肝病 (NAFLD) 的研究。

  • GC69039 structure
    GC69039Edratide
    CAS: 433922-67-9
    纯度: >98.00%

    Edratide (TV 4710) 是一种由 19 个氨基酸组成的合成肽,它基于人类抗 DNA 抗体的互补决定区 1 (CDR1),表达主要独特型 16/6 Id。Edratide 降低细胞凋亡 (apoptosis) (Apoptosis) 率并下调 caspase-8 和 caspase-3,上调 Bcl-xL。Edratide 具有研究系统性红斑狼疮 (SLE) 的潜力。

  • GC69054 structure
    GC69054Elsilimomab
    CAS: 468715-71-1
    纯度: >95.00%

    Elsilimomab (B-E8) 是一种抗白介素-6 (IL-6) 的 IgG1 单克隆抗体,其 KD 为 22 pM,IC50 为 1.4 nM。Elsilimomab 可用于多发性骨髓瘤、肾细胞癌和类风湿性关节炎 (RA) 的研究。

  • GC69056 structure
    GC69056Emapalumab
    CAS: 1709815-23-5
    纯度: >98.00%

    Emapalumab (NI-0501) 是一种人源化 IgG1 单克隆抗体,可非竞争性地抑制 IFN-γ。Emapalumab 与游离的 IFN-γ 以及与其受体结合的 IFN-γ 具有高亲和力 (Kd=1.4 pM)。Emapalumab 可用于噬血细胞性淋巴组织细胞增多症 (HLH) 的研究。

  • GC69070 structure
    GC69070Enpp/Carbonic anhydrase-IN-1
    CAS: 2883495-35-8
    纯度: >99.00%

    Enpp/Carbonic anhydrase-IN-1 (compound 1e) 是一种有效的 Enpp 和 carbonic anhydrase 抑制剂,对 NPP1、NPP2、NPP3、CA-II、CA-IX 的 IC50 值分别 1.36、1.35、3.00、0.88、1.02 μM。Enpp/Carbonic anhydrase-IN-1 对癌细胞具有抗增殖活性,对正常细胞具有低细胞毒性。Enpp/Carbonic anhydrase-IN-1 诱导细胞凋亡 (Apoptosis)。

  • GC69093 structure
    GC69093Faralimomab
    CAS: 167816-91-3
    纯度: >95.00%

    Faralimomab (64G12) 是一种免疫调节剂,也是一种小鼠抗 IFNA1 IgG1 单抗。

  • GC69104 structure
    GC69104Fezakinumab
    CAS: 1007106-86-6
    纯度: >99.00%

    Fezakinumab 是一种白细胞介素 22 (IL-22) 单克隆抗体。Fezakinumab 可用于银屑病、类风湿性关节炎等炎症性疾病的研究。

  • GC69105 structure
    GC69105FG-3019
    CAS: 946415-13-0
    纯度: >95.00%

    FG-3019 (Pamrevlumab) 是一种重组人源化抗体,可与结缔组织生长因子 (CTGF) 结合。FG-3019 可用于特发性肺纤维化 (IPF) 的研究。

  • GC69116 structure
    GC69116Fletikumab
    CAS: 1357158-22-5
    纯度: >99.00%

    Fletikumab (NNC0109-0012) 是一种靶向 IL-20 的单克隆抗体。Fletikumab 可用于炎症研究,如类风湿关节炎。

  • GC69144 structure
    GC69144Galectin-3 antagonist 1
    CAS: 2921603-03-2
    纯度: >99.00%

    Galectin-3 antagonist 1 (compound 15) 是一种有效的选择性 Galectin-3 (Gal-3) 拮抗剂,Kd 值为 5.3 μM。同时,Galectin-3 antagonist 1 结合多种 Galectin,Kd 值分别为 250 μM (GAl-4N)、18 μM (Gal-4C)、450 μM (Gal-8C)。

  • GC69156 structure
    GC69156GDC-2394
    CAS: 2238822-07-4

    GDC-2394 是一种口服有效、选择性的 NLRP3 抑制剂,同时也抑制 IL-1β,IC50 为 0.4 μM (human IL-1β) 和 0.1 μM (mouse IL-1β)。GDC-2394 抑制 NLRP3 诱导的 caspase-1 活性,但不抑制 NLRC4 依赖的炎症小体激活。

  • GC69160 structure
    GC69160Gevokizumab
    CAS: 1129435-60-4
    纯度: >98.00%

    Gevokizumab 是一种有效的抗 IL-1β 抗体,通过变构机制负向调节 IL-1β 信号。Gevokizumab 降低 IL-1β 对 IL-1 受体 I 型 (IL-1RI) 信号受体的结合亲和力,而不影响 IL-1 反调节诱饵受体 (IL-1 受体 II 型)。

  • GC69169 structure
    GC69169GLPG3970
    CAS: 2403733-82-2

    GLPG3970 (compound 88) 是一类首创的 SIK2/SIK3 抑制剂。GLPG3970 可用于炎症和自身免疫性疾病的研究。

  • GC69178 structure
    GC69178Glychionide A
    CAS: 119152-50-0

    Glychionide A 是一种黄酮苷,存在于 Glychirriza glabra 的根中。Glychionide A 促进 PANC-1 胰腺癌细胞的凋亡和自噬。Glychionide A 可用于癌症的研究。

  • GC69216 structure
    GC69216HE 3286
    CAS: 1001100-69-1
    纯度: >95.00%

    HE 3286 是天然抗炎类固醇 β-AET 的合成衍生物。HE 3286 是具有口服活性的 NF-κB 部分抑制剂。HE 3286 降低了促炎信号,包括 IL-6 和基质金属肽酶 3。HE 3286 可自由穿过小鼠血脑屏障。HE 3286 可用于溃疡性结肠炎、关节炎、实验性自身免疫性脑脊髓炎的研究。

  • GC69259 structure
    GC69259IFN-γ Antagonist 1 acetate
    纯度: >99.50%

    IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) acetate 是一种干扰素 γ (IFN-γ) 拮抗剂。IFN-γ Antagonist 1 抑制 IFN-γ 诱导的 HLR/DR 抗原在 Colo 205 细胞中的表达,IC50 值约为 35 μM。IFN-γ Antagonist 1 在免疫调节中有潜在应用。

  • GC69262 structure
    GC69262IL-17 modulator 3
    CAS: 2467731-88-8
    纯度: >99.00%

    IL-17 modulator 3 是 IL-17 调节剂 (US20200247785A1)。IL-17 modulator 3 可用于炎症、癌症和自身免疫性疾病的研究。

  • GC69280 structure
    GC69280iNOs-IN-1

    iNOs-IN-1 (YPW) 是一种有效的诱导型一氧化氮合酶 (inducible nitric oxide synthase, iNOS) 抑制剂。iNOs-IN-1 在小鼠巨噬细胞中能显著抑制 IL-6 和 iNOS 的表达,也能抑制 LPS 诱导的 NO 生成,且具有剂量依赖性。具有抗炎作用。

  • GC69302 structure
    GC69302Itepekimab
    CAS: 2226742-52-3
    纯度: >95.00%

    Itepekimab (REGN-3500) 是一种 IL-33 的单克隆抗体。Itepekimab 在前期临床研究中可减少气道炎症和相关组织损伤。Itepekimab 在哮喘、慢性阻塞性肺病 (COPD) 和特应性皮炎 (AD) 中具有潜在作用。

  • GC69311 structure
    GC69311JC2-11
    CAS: 937820-89-8
    纯度: >98.00%

    JC2-11 是一种炎症小体抑制剂。JC2-11 抑制含有募集结构域的蛋白质 NLRC 4、黑色素瘤 2 中缺失 (AIM 2) 和非典型 (NC) 炎症小体。JC2-11 减少了炎症小体中 caspase-1 (p20) 的分泌、gasdermin D (GSDMD) 的裂解、IL-1β 和乳酸脱氢酶 (LDH) 的释放。JC2-11 通过破坏活性氧的产生和 caspase-1 的活性来抑制炎症小体的活化。